Back to search results

CPAP for Type 1 Diabetes and Obstructive Sleep Apnea

This study is looking at how treating obstructive sleep apnea (OSA) (a common sleep disorder where breathing repeatedly stops and starts during sleep) might affect blood sugar levels in adults with Type 1 Diabetes (T1D). Researchers want to see if using continuous positive airway pressure (CPAP) (a device that helps keep your airway open while you sleep) every night can improve blood sugar control. You might be able to join if you are 18 to 50 years old, have Type 1 Diabetes and use an insulin pump and continuous glucose monitor (CGM), and have been diagnosed with OSA through a home sleep test. The main goal is to see how much blood sugar levels change within three months of starting CPAP. The study plans to enroll 40 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 40 participants. All participants will receive continuous positive airway pressure (CPAP) treatment.
What's involved
Participants will use CPAP every night from 11:00 PM to 7:00 AM. Blood sugar levels will be measured within three months of screening.
Compensation
Not stated in the trial record.
Follow-up
Participants' glycemic variability will be measured within 3 months of screening.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06915831

Type 1 Diabetes and Obstructive Sleep Apnea

Recruiting
NAAges 18–50Interventional
University of Chicago
~40 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:Continuous positive airway pressure (CPAP)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glycemic variability
Measured over Within 3 months of screening

Conditions

Sleep Apnea, Obstructive
Type 1 Diabetes (T1D)

Explore related trials

Obstructive Sleep ApneaType 1 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Esra Tasali, MD · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Esra Tasali, MD
[email protected]
7738342663
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: 18 to 50 years old
Type 1 Diabetes on insulin pump therapy and using a CGM device with an GMI (glucose management indicator) between 5.5 and 8.5% with hemoglobin in the normal range at screening
OSA by home sleep apnea test

Exclusion

Regular and adherent CPAP use per clinical guidelines
Requiring oxygen or advanced positive airway pressure modalities during sleep
Having a 'fall-asleep' or 'near miss' accident in the past 6-months
Shift work
Severe hypoglycemia (≥1 episode in the past 3 months or diagnosis of hypoglycemic unawareness)
≥1 trip to emergency room for poor glucose management in the past 6 months
Proliferative retinopathy
Fasting triglycerides \>400mg/dL,
Liver transaminases \>2 times upper limit of normal,
Renal transplantation or serum creatinine \>1.5 mg/dL
Anemia (hemoglobin \<13.0g/dL in men or \<11.6g/dL in women)
Acute coronary syndrome or stroke past 6 months
Severe hypertension (blood pressure\>180/105 mmHg)
Any other significant health condition: unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class\>2, pulmonary disease with dependence on oxygen or daily use of bronchodilators, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly)
Recent major surgery
Major psychiatric disorder
Subjects will also be excluded if taking medications that can confound metabolic assessments including systemic glucocorticoids, antipsychotics, thiazide diuretics, beta-blockers, daily use of aminophylline or theophylline, or use of any immunosuppressant.
Currently pregnant or trying to get pregnant or nursing
Smoking, alcohol or illegal drug abuse

What this trial measures

  • Glycemic variabilityWithin 3 months of screening

    Glycemic variability will be calculated using a standard metric as percent coefficient of variation (% CV) of glucose values obtained from continuous glucose monitoring (CGM).